NASDAQ:HSIC - Henry Schein Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $90.00
  • Forecasted Upside: 17.77 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.03 (0.04%)

This chart shows the closing price for HSIC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Henry Schein Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HSIC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HSIC

Analyst Price Target is $90.00
▲ +17.77% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Henry Schein in the last 3 months. The average price target is $90.00, with a high forecast of $91.00 and a low forecast of $89.00. The average price target represents a 17.77% upside from the last price of $76.42.

This chart shows the closing price for HSIC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Henry Schein. This rating has held steady since April 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 3 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 3 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 3 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 3 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/5/2021Barrington ResearchBoost Price TargetOutperform$80.00 ➝ $91.00Low
5/5/2021Robert W. BairdBoost Price TargetOutperform$79.00 ➝ $90.00Medium
5/4/2021Piper SandlerBoost Price TargetOverweight$79.00 ➝ $89.00Medium
2/18/2021Barrington ResearchBoost Price TargetOutperform$72.00 ➝ $80.00High
2/8/2021Piper SandlerReiterated RatingOverweight$83.00Low
1/4/2021Robert W. BairdUpgradeNeutral ➝ Outperform$70.00 ➝ $79.00N/A
11/3/2020Barrington ResearchUpgradeMarket Perform ➝ Outperform$72.00Medium
5/7/2020UBS GroupLower Price TargetSell$60.00 ➝ $50.00High
5/6/2020Robert W. BairdBoost Price TargetNeutral$58.00 ➝ $60.00Low
5/6/2020Barrington ResearchDowngradeOutperform ➝ Market PerformMedium
5/5/2020CfraLower Price TargetHold$69.00 ➝ $60.00Medium
4/19/2020Credit Suisse GroupReiterated RatingHold$59.00Low
4/7/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$64.00 ➝ $59.00Low
4/2/2020Wolfe ResearchUpgradePeer Perform ➝ Outperform$68.00Medium
3/31/2020BarclaysLower Price TargetEqual Weight$58.00 ➝ $57.00Medium
3/20/2020BarclaysReiterated RatingHold$58.00High
2/24/2020JPMorgan Chase & Co.Boost Price TargetNeutral$66.00 ➝ $68.00Medium
1/9/2020Bank of AmericaDowngradeNeutral ➝ Underperform$65.00High
1/3/2020Evercore ISIDowngradeIn-Line ➝ UnderperformLow
1/2/2020Robert W. BairdDowngradeOutperform ➝ NeutralLow
12/3/2019Bank of AmericaBoost Price TargetNeutral$69.00 ➝ $71.00Low
11/11/2019Piper Jaffray CompaniesBoost Price TargetOverweight$72.00 ➝ $80.00Low
11/6/2019Barrington ResearchReiterated RatingBuy$75.00Low
11/1/2019Cleveland ResearchReiterated RatingHoldN/A
8/7/2019Barrington ResearchReiterated RatingBuy$75.00Medium
8/7/2019William BlairDowngradeOutperform ➝ Market PerformHigh
5/30/2019Wolfe ResearchInitiated CoverageUnderperform ➝ UnderperformLow
5/15/2019SVB LeerinkReiterated RatingOutperform ➝ Market Perform$75.00 ➝ $70.00Low
5/8/2019Barrington ResearchBoost Price TargetOutperform$72.00 ➝ $75.00Medium
5/8/2019Craig HallumReiterated RatingBuy$72.00 ➝ $77.00High
5/2/2019Cleveland ResearchReiterated RatingHoldLow
4/17/2019GuggenheimInitiated CoverageBuy ➝ Buy$72.00Medium
3/25/2019Robert W. BairdReiterated RatingNeutralMedium
2/21/2019Royal Bank of CanadaLower Price TargetAverage ➝ Sector Perform$62.00Medium
2/21/2019BarclaysLower Price TargetEqual Weight ➝ Equal Weight$73.00 ➝ $63.00Low
2/21/2019Barrington ResearchReiterated RatingBuy$72.00Low
2/19/2019Craig HallumLower Price TargetBuy$96.00 ➝ $72.00Low
2/12/2019Royal Bank of CanadaLower Price TargetPositive ➝ Sector Perform$69.00Low
1/17/2019UBS GroupInitiated CoverageSell ➝ Sell$73.00Medium
1/3/2019Evercore ISIDowngradeIn-Line ➝ Underperform$76.39Medium
1/2/2019Robert W. BairdDowngradeOutperform ➝ Neutral$76.60High
11/29/2018Piper Jaffray CompaniesReiterated RatingOverweight$96.00Low
11/8/2018Barrington ResearchBoost Price TargetReduce ➝ Outperform$92.00 ➝ $96.00Medium
10/25/2018Edward JonesDowngradeHold ➝ SellLow
10/20/2018The Goldman Sachs GroupInitiated CoverageHold$78.00Low
10/19/2018The Goldman Sachs GroupReiterated RatingNeutral ➝ NeutralLow
10/9/2018Morgan StanleyBoost Price TargetUnderweight ➝ Underweight$65.00 ➝ $66.00Low
10/4/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$90.00 ➝ $95.00Low
9/24/2018Cleveland ResearchReiterated RatingHoldLow
8/7/2018SVB LeerinkSet Price TargetBuy$100.00Low
8/7/2018Barrington ResearchReiterated RatingBuy$92.00Low
8/7/2018Craig HallumBoost Price TargetBuy$83.00 ➝ $96.00Low
8/7/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$83.00 ➝ $90.00Low
8/7/2018Stifel NicolausBoost Price TargetHold ➝ Hold$76.00 ➝ $81.00High
5/10/2018Barrington ResearchLower Price TargetOutperform$88.00Low
5/9/2018BarclaysReiterated RatingHold$73.00Low
4/24/2018Northcoast ResearchSet Price TargetBuy$102.00Low
4/24/2018Deutsche Bank AktiengesellschaftBoost Price TargetBuy ➝ Buy$79.00 ➝ $82.00High
4/24/2018The Goldman Sachs GroupDowngradeBuy ➝ NeutralHigh
4/4/2018SVB LeerinkUpgradeMarket Perform ➝ Outperform$75.00High
3/8/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$71.00Low
2/27/2018Bank of AmericaInitiated CoverageNeutral ➝ Neutral$76.00Low
2/21/2018Barrington ResearchReiterated RatingOutperformLow
2/21/2018SVB LeerinkSet Price TargetMarket Perform ➝ Hold$77.00 ➝ $75.00Low
2/15/2018JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Neutral$79.00 ➝ $77.00Low
2/13/2018SVB LeerinkReiterated RatingHoldHigh
1/4/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$81.00Medium
12/27/2017Piper Jaffray CompaniesReiterated RatingBuy$78.00Low
12/8/2017Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$79.00Low
12/6/2017Morgan StanleyDowngradeEqual Weight ➝ Underweight$88.00High
11/28/2017Credit Suisse GroupReiterated RatingNeutral$87.50 ➝ $80.00Low
11/28/2017StephensInitiated CoverageEqual ➝ Equal Weight$76.00Low
11/7/2017Jefferies Financial GroupLower Price TargetHold$89.00 ➝ $74.00N/A
11/7/2017SVB LeerinkReiterated RatingMarket Perform$87.50 ➝ $77.00N/A
11/7/2017Stifel NicolausLower Price TargetHold ➝ Hold$89.00 ➝ $77.00N/A
11/7/2017Craig HallumUpgradeHold ➝ BuyN/A
11/7/2017Royal Bank of CanadaLower Price TargetSector Perform ➝ Sector Perform$91.00 ➝ $82.00N/A
10/20/2017Jefferies Financial GroupReiterated RatingHold$89.00N/A
10/19/2017Robert W. BairdSet Price TargetBuy$95.00N/A
10/19/2017Stifel NicolausReiterated RatingHold$89.00N/A
9/28/2017Jefferies Financial GroupReiterated RatingHold$88.50Low
9/21/2017Morgan StanleyInitiated CoverageEqual ➝ Equal Weight$88.00Low
9/19/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$91.00High
9/15/2017UBS GroupReiterated RatingBuyN/A
9/15/2017Piper Jaffray CompaniesUpgradeNeutral ➝ OverweightLow
8/29/2017Credit Suisse GroupReiterated RatingHold$87.50Low
8/7/2017Northcoast ResearchUpgradeNeutral ➝ Buy$109.00High
7/21/2017Jefferies Financial GroupReiterated RatingHold$88.50Low
7/13/2017Credit Suisse GroupReiterated RatingHold$80.00 ➝ $80.00Low
7/6/2017Stifel NicolausReiterated RatingHoldLow
6/12/2017Piper Jaffray CompaniesInitiated CoverageNeutral ➝ Neutral$100.00Low
5/10/2017Barrington ResearchBoost Price TargetOutperform ➝ Outperform$98.00 ➝ $99.00Low
5/10/2017Stifel NicolausBoost Price TargetHold ➝ Hold$87.00 ➝ $89.00Low
4/11/2017Craig HallumInitiated CoverageHoldLow
3/15/2017Deutsche Bank AktiengesellschaftInitiated CoverageHold ➝ Hold$87.00Low
2/28/2017Jefferies Financial GroupReiterated RatingHold$82.50N/A
2/22/2017SVB LeerinkSet Price TargetHold$91.50N/A
2/22/2017Barrington ResearchReiterated RatingOutperform ➝ Outperform$92.50 ➝ $98.00N/A
2/21/2017Evercore ISIBoost Price TargetHold$80.00 ➝ $89.00N/A
1/10/2017GabelliUpgradeHold ➝ Buy$104.00N/A
1/3/2017Robert W. BairdUpgradeNeutral ➝ Outperform$82.00 ➝ $85.00N/A
12/6/2016Northcoast ResearchDowngradeBuy ➝ NeutralN/A
11/3/2016JPMorgan Chase & Co.Reiterated RatingHold$81.50N/A
11/3/2016SVB LeerinkReiterated RatingHoldN/A
10/14/2016Robert W. BairdDowngradeOutperform ➝ Neutral$88.00 ➝ $82.00N/A
10/11/2016The Goldman Sachs GroupUpgradeNeutral ➝ Buy$92.50N/A
10/5/2016UBS GroupInitiated CoverageBuy$93.00N/A
10/4/2016Robert W. BairdReiterated RatingOutperform$87.50 ➝ $88.00N/A
9/12/2016Bank of AmericaInitiated CoverageBuy$92.50N/A
(Data available from 6/23/2016 forward)
Henry Schein logo
Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates in two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
Read More

Today's Range

Now: $76.42
Low: $75.84
High: $76.62

50 Day Range

MA: $76.48
Low: $70.00
High: $82.97

52 Week Range

Now: $76.42
Low: $54.25
High: $83.45


503,619 shs

Average Volume

990,911 shs

Market Capitalization

$10.75 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Henry Schein?

The following equities research analysts have issued research reports on Henry Schein in the last twelve months: Barrington Research, Piper Sandler, Robert W. Baird, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for HSIC.

What is the current price target for Henry Schein?

3 Wall Street analysts have set twelve-month price targets for Henry Schein in the last year. Their average twelve-month price target is $90.00, suggesting a possible upside of 17.8%. Barrington Research has the highest price target set, predicting HSIC will reach $91.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $89.00 for Henry Schein in the next year.
View the latest price targets for HSIC.

What is the current consensus analyst rating for Henry Schein?

Henry Schein currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HSIC will outperform the market and that investors should add to their positions of Henry Schein.
View the latest ratings for HSIC.

What other companies compete with Henry Schein?

Other companies that are similar to Henry Schein include McKesson, AmerisourceBergen, Cardinal Health, Patterson Companies and Owens & Minor.

How do I contact Henry Schein's investor relations team?

Henry Schein's physical mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company's listed phone number is (631) 843-5500 and its investor relations email address is [email protected] The official website for Henry Schein is